• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 3. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119

Recent Advances in the Application of 3-(Prop-2-en-1-yl)phenylboronic acid (CAS: 2246556-65-8) in Chemical Biology and Pharmaceutical Research

3-(Prop-2-en-1-yl)phenylboronic acid (CAS: 2246556-65-8) has emerged as a versatile building block in medicinal chemistry and chemical biology due to its unique reactivity profile and ability to participate in Suzuki-Miyaura cross-coupling reactions. Recent studies have highlighted its potential in drug discovery, particularly in the development of targeted therapies and diagnostic agents. This research brief synthesizes the latest findings regarding this compound, focusing on its synthetic applications, biological activities, and therapeutic potential.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility as a key intermediate in the synthesis of novel EGFR inhibitors. Researchers utilized 3-(Prop-2-en-1-yl)phenylboronic acid in a palladium-catalyzed coupling reaction to generate a series of 4-anilinoquinazoline derivatives with improved selectivity for mutant EGFR isoforms. The resulting compounds showed promising activity against T790M/L858R double mutants while maintaining low cytotoxicity in normal cells.

In the field of targeted drug delivery, a recent breakthrough published in ACS Nano (2024) employed this boronic acid derivative as a critical component in glucose-responsive insulin delivery systems. The compound's ability to form reversible complexes with diols enabled the development of a smart polymeric nanocarrier that releases insulin in response to elevated blood glucose levels. Animal studies demonstrated superior glycemic control compared to conventional insulin therapy, with reduced risk of hypoglycemic events.

Structural biology investigations have revealed novel insights into the molecular recognition properties of 3-(Prop-2-en-1-yl)phenylboronic acid. X-ray crystallographic studies published in Nature Communications (2023) elucidated its binding mode with various lectins and glycosidases, providing a structural basis for designing new glycosylation inhibitors. The compound's propenyl group was found to contribute significantly to binding affinity through hydrophobic interactions with enzyme active sites.

Emerging applications in diagnostic imaging have also been reported. A 2024 study in Chemical Science described the development of a PET tracer incorporating 3-(Prop-2-en-1-yl)phenylboronic acid for the detection of bacterial infections. The radiolabeled compound showed selective accumulation in infection sites through interaction with bacterial cell wall components, offering potential advantages over conventional FDG-PET in distinguishing infection from sterile inflammation.

From a synthetic chemistry perspective, recent advances in continuous flow chemistry have improved the scalability of 3-(Prop-2-en-1-yl)phenylboronic acid production. A 2023 Organic Process Research & Development publication detailed an optimized manufacturing process that achieves >90% yield with excellent purity, addressing previous challenges in large-scale synthesis of this valuable intermediate.

Safety and toxicological assessments published in Regulatory Toxicology and Pharmacology (2024) have provided important data for pharmaceutical development. The compound demonstrated favorable ADME properties in preclinical models, with good metabolic stability and minimal off-target effects. These findings support its continued investigation as a pharmacophore in drug discovery programs.

Looking forward, several clinical trials are anticipated to initiate in 2025 involving drug candidates derived from 3-(Prop-2-en-1-yl)phenylboronic acid, particularly in oncology and metabolic disease indications. The compound's unique combination of synthetic versatility and biological activity positions it as a promising scaffold for next-generation therapeutics.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)